Literature DB >> 23996469

Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Miglena G Prabagar1, Hyeong-jwa Choi, Jin-Yeon Park, Sohee Loh, Young-Sun Kang.   

Abstract

Immunoglobulins are glycoproteins produced by the cells of the immune system. Their primary function is to protect the body from pathogenic infection. Moreover, a concentrated polyclonal mixture of immunoglobulin G (IgG), the so-called intravenous IgG (IVIG), has been used to treat various chronic and systemic disorders of the immune system. Studies on the effects of IVIG in autoimmune disease models have revealed that IgG Fc fragments confer protection against various autoimmune diseases. The identification of this IgG Fc immunomodulatory component is important for the development of IVIG substitutes. The focus of this review is to introduce one of the Fc regulatory entities and to provide a summary of the current knowledge of the putative general mechanisms underlying IVIG activity in vivo on the basis of these Fc fragments. We also address the recent insights into several approaches for the development of IVIG substitutes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23996469     DOI: 10.1007/s10238-013-0255-4

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  105 in total

Review 1.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  The relationship between exposed galactose and N-acetylglucosamine residues on IgG in rheumatoid arthritis (RA), juvenile chronic arthritis (JCA) and Sjögren's syndrome (SS).

Authors:  A Bond; A Alavi; J S Axford; P Youinou; F C Hay
Journal:  Clin Exp Immunol       Date:  1996-07       Impact factor: 4.330

3.  IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1.

Authors:  Inessa Schwab; Markus Biburger; Gerhard Krönke; Georg Schett; Falk Nimmerjahn
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

4.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

5.  Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function.

Authors:  Aharon Kessel; Hana Ammuri; Regina Peri; Elsa R Pavlotzky; Miri Blank; Yehuda Shoenfeld; Elias Toubi
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

6.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

Review 7.  Recombinant immunoglobulin-based epitope delivery: a novel class of autoimmune regulators.

Authors:  William J Phillips; Dan J Smith; Constantin A Bona; Adrian Bot; Habib Zaghouani
Journal:  Int Rev Immunol       Date:  2005 Sep-Dec       Impact factor: 5.311

8.  IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes.

Authors:  Jean-François Séïté; Divi Cornec; Yves Renaudineau; Pierre Youinou; Rizgar A Mageed; Sophie Hillion
Journal:  Blood       Date:  2010-06-01       Impact factor: 22.113

9.  Lack of CD4⁺CD25⁺FOXP3⁺ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease.

Authors:  Yu Hirabayashi; Yoshiyuki Takahashi; Yinyan Xu; Kazuyuki Akane; Itzel Bustos Villalobos; Yusuke Okuno; Shinji Hasegawa; Hideki Muramatsu; Asahito Hama; Taichi Kato; Seiji Kojima
Journal:  Eur J Pediatr       Date:  2013-01-23       Impact factor: 3.183

10.  Mycobacteria target DC-SIGN to suppress dendritic cell function.

Authors:  Teunis B H Geijtenbeek; Sandra J Van Vliet; Estella A Koppel; Marta Sanchez-Hernandez; Christine M J E Vandenbroucke-Grauls; Ben Appelmelk; Yvette Van Kooyk
Journal:  J Exp Med       Date:  2003-01-06       Impact factor: 14.307

View more
  8 in total

Review 1.  Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

Authors:  Luca Cantarini; Donato Rigante; Antonio Vitale; Salvatore Napodano; Lazaros I Sakkas; Dimitrios P Bogdanos; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

2.  Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis.

Authors:  Hao Li; Xing-Xing Wang; Bin Wang; Lei Fu; Guan Liu; Yu Lu; Min Cao; Hairong Huang; Babak Javid
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

3.  Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells.

Authors:  Zihan Wang; Zihan Geng; Wenwei Shao; Enyang Liu; Jingxuan Zhang; Jingshu Tang; Pingzhang Wang; Xiuyuan Sun; Lin Xiao; Weiyan Xu; Youhui Zhang; Heng Cui; Liang Zhang; Xi Yang; Xiaohong Chang; Xiaoyan Qiu
Journal:  Cell Mol Immunol       Date:  2019-11-21       Impact factor: 22.096

4.  A DNA Vaccine Encoding the Gn Ectodomain of Rift Valley Fever Virus Protects Mice via a Humoral Response Decreased by DEC205 Targeting.

Authors:  Tiphany Chrun; Sandra Lacôte; Céline Urien; Charles-Adrien Richard; Matthias Tenbusch; Nicolas Aubrey; Coralie Pulido; Latifa Lakhdar; Philippe Marianneau; Isabelle Schwartz-Cornil
Journal:  Front Immunol       Date:  2019-04-25       Impact factor: 7.561

Review 5.  COVID-19: Immunology and treatment options.

Authors:  Susanna Felsenstein; Jenny A Herbert; Paul S McNamara; Christian M Hedrich
Journal:  Clin Immunol       Date:  2020-04-27       Impact factor: 3.969

6.  Intravenous Immunoglobulin in the Management of Lupus Erythematosus Panniculitis.

Authors:  Nada G AlQadri; Bayan AlNooh; Malak M AlTewerki; Ahmad Almotairi; Saad Alajlan
Journal:  Cureus       Date:  2020-01-27

7.  Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system.

Authors:  Cristina Segú-Vergés; Silvia Caño; Elisabeth Calderón-Gómez; Helena Bartra; Teresa Sardon; Srini Kaveri; José Terencio
Journal:  Front Immunol       Date:  2022-09-30       Impact factor: 8.786

8.  Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?

Authors:  Laetitia Sordé; Sebastian Spindeldreher; Ed Palmer; Anette Karle
Journal:  Immun Inflamm Dis       Date:  2017-05-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.